Controlling Shareholder Richard Griffiths Reduces Stake to 21.7% After $16.3M Sales
SLN has more than doubled off its 52-week low of $4.19.
Summary
Controlling shareholder Richard Griffiths sold $16.3 million in ADSs, decreasing his stake to 21.7% of Silence Therapeutics plc, following recent share capital increases.
Key Events · Ownership and Investor Activity · SLN
-
Significant Insider Sales
Richard Griffiths, a controlling shareholder and director, sold 1,544,374 ADSs for aggregate proceeds of $16.3 million in open market transactions between June 29 and July 6, 2026.
-
Reduced Ownership Stake
Following these sales and dilution from an increase in the company's share capital, Mr. Griffiths' aggregate ownership (including controlled entities) has decreased to 30,844,458 ordinary shares, representing 21.7% of the company's outstanding shares.
-
Follows Recent ATM Program
This reduction in stake by a major shareholder occurs after the company recently activated a $100 million At-The-Market (ATM) offering program in late May, which also contributes to potential share dilution.
Analysis · SLN · Life Sciences
Richard Griffiths, a controlling shareholder and director, reported selling $16.3 million worth of ADSs, reducing his aggregate ownership to 21.7%. This significant reduction in stake by a key insider, combined with dilution from recent share capital increases and the company's active ATM program, indicates a notable shift in his investment position and could contribute to market overhang.
At the time of this filing, SLN was trading at $10.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $479.4M. The 52-week trading range was $4.19 to $11.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.